Sign Up
Stories
Breakthrough Canine Cancer Treatment Approval
Share
AI-Powered Antigen Research Partnership
Adagene Advances Clinical Collaboration
Advancements in Antibodies to Protect Im...
AB-2100 Phase 1/2 Trial Initiated
BioNTech's mRNA Cancer Vaccine Progress
Breakthrough Cancer Immunotherapy for Do...
Overview
API
ELIAS Animal Health gains USDA approval for ECI® cancer immunotherapy technology to treat osteosarcoma in dogs, showing positive outcomes in clinical testing. Plans include enhancing accessibility through apheresis center expansion and exploring immune checkpoint inhibitor combinations.
Ask a question
How could the integration of immune checkpoint inhibitors with ECI® influence the broader landscape of cancer immunotherapy research and development?
How might the success of ECI® in dogs impact the future of cancer treatment for other animals or even humans?
What challenges and ethical considerations arise with the expansion of advanced cancer treatments in veterinary care?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Dec 2023
Jan 2024
Feb 2024
Coverage
aaha.